Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Subscribe To Our Newsletter & Stay Updated